Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 5, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions
Allergy to Cats
Interventions
DRUG

Zafirlukast

Oral zafirlukast is approved to treat asthma and been shown in previous trials to be effective in blocking or mitigating the symptoms of people allergic to cat dander

All Listed Sponsors
lead

Allergy & Asthma Medical Group & Research Center

OTHER